This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of alpha-1 antitrypsin (AAT) augmentation therapy with Prolastin or Prolastin-C over other alpha-1 proteinase inhibitors (A1PIs), for management of lung disease in patients with AAT deficiency (AATD).